Trial
NCT06435845
Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Rallybio
Collaborators
—
Condition
Fetal and Neonatal Alloimmune Thrombocytopenia
Intervention
Anti-(integrin beta-3) human monoclonal antibody
Why stopped
This study was terminated early by the sponsor due to insufficient drug exposure to achieve the intended therapeutic effect.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-06